November 2006

GB spins its information business into Hound Information
General Biologic has spun its reports and database information products into a new division, GB Information. GBI Information will focus initially on the business information needs of the pharmaceutical industry, and will provide information products and services through a newly established delivery platform, www.gbipharma.com. "Placing our valuable information assets into Hound Information will bring greater customer focus and scalability to the enterprise," commented Matthew Chervenak.

October 2006

GB’s Industrial Biotechnology in China report highlighted in industry journal
GB's Industrial Biotechnology in China report is highlighted in the Fall 2006 issue of Industrial Biotechnology journal (Mary Ann Liebert, Inc. Volume 2, Number 3). The introduction section of the report is excerpted.

September 2006

GB presents at Follow-On Biologics Forum in Washington DC
GB presented a "State of China’s Biopharmaceutical Industry" talk at IBC's annual event. Topics covered included China's impact on the global pharmaceutical industry, case studies on key players within the industry, and price competition's impact on the structure of the industry.

August 2006

GB releases Industrial Biotechnology in China
GB released Industrial Biotechnology in China. This report is essential for understanding China’s industrial biotech players, trends, government actions, research & development, and markets. The product is available for purchase on GB’s website at www.generalbiologic.com.

July 2006

GB presents at Third Annual World Congress on Industrial Biotechnology and Bioprocessing
The Third Annual World Congress on Industrial Biotechnology and Bioprocessing was held July, 2006 in Toronto, Canada. Matthew Chervenak hosted a panel on the topic of “Biofuels and Biobased Business in Asia”.

June 13-15, 2006

GB Sponsors and Presents at BioPharma Opportunities China
BioPharma Opportunities China was held on June 13-15, 2006 in Shanghai. GB was among the sponsors of the event. GB presented on opportunities in innovation and outsourcing in China. The event prompted considerable interest by investors, pharmaceutical, and biotechnology companies.

May 2006

GB publishes China Biotech 2006 report
GB published China Biotech 2006. Fully updated and expanded from the 2004 edition, this report is essential for understanding China’s emerging innovators, identifying potential clients and partners, and staying abreast of developments in China’s dynamic industry. The product is available for purchase on GB’s website at www.generalbiologic.com.

May 2006

GB brings Bio-services in China report up to date with 2006 edition
GB fully updated and expanded its China Bio-services report. Bio-services in China 2006 is an essential resource for biotechnology and pharmaceutical companies aiming to increase R&D productivity and reduce costs through outsourcing to bio-services companies. The product is available for purchase on GB’s website at www.generalbiologic.com.

April 24-26, 2006

GB presents at Advances in Drug Discovery and Development
Advances in Drug Discovery and Development was held April 24-26, 2006 in Tokyo, Japan. GB president Matthew Chervenak presented on innovation and outsourcing in China. An Asia-wide event, the conference brought in participants from North America, Japan, India, and China.

April 2006

GB publishes Chemical Synthesis in China
GB published a new report covering the exciting area of custom chemical synthesis in China. This report provides a comprehensive resource for Western chemical companies and new drug research entities looking to outsource synthesis. Critical information is presented for those interested in sourcing, OEM, or exploring the custom chemical synthesis business in China. The product is available for purchase on GB’s website at www.generalbiologic.com.

February 14-15, 2006

GB presents at BIO CEO & Investor Conference 2006
The annual BIO CEO & Investor Conference 2006 was held February 14-15, 2006 at the Waldorf-Astoria in New York City. GB president Matthew Chervenak sat on a panel with Jim Stoppert, Senior Director of Bio-Products at Cargill and Roger Wyse, Managing Director of Burrill & Co that was moderated by Brent Erickson, Vice President of the Industrial and Environmental Section at the Biotechnology Industry Organization. The panel addressed trends in industrial biotechnology and kicked off company presentations for the day.

September 2005

GB moves to new office
GB moved to a new office within the city-center of Shanghai. We welcome old and new friends to come and visit our new digs! Suite 506, Asia-Pacific Building 333 Zhaojiabang Rd. Shanghai, P.R. China 200032 Phone: +86-21-64174301 Fax: +86-21-64173950

June 19-22, 2005

GB presents at BIO meeting 2005
GB presents at the annual BIO meeting, held June 19-22 in Philadelphia, Pa., US. The event, hosted by Biotechnology Industry Association, invited GB president Matthew Chervenak to speak about China's progress in the world of bio-business. The seminar was attended by foreign investors and pharmaceutical companies.

April 27 – 29, 2005

GB Presents at Follow-On Biologics Forum
GB presented at the Follow-on Biologics Forum, held April 27-29, in Washington, D.C. The event included a number of branded and generic manufacturers, along with a strong contingent of lawyers and investors. GB’s Matthew Chervenak introduced China’s follow-on biologics industry, along with lessons learned and suggestions for multinational enterprises.

March 1, 2005

GB publishes its report on Bio-Distributors in China
GB analysts release "Bio-Distributors China 2005", a fundamental resource for life science suppliers seeking to reach customers in China. The report offers an overview of the industry environment for China's more than 180 distributors. "This report provides the foundation from which companies may craft an informed distribution strategy that maximizes potential in this rapidly changing market." says GB President, Matthew Chervenak.

February 1, 2005

GB releases its report on the antibody industry in China
"Antibodies in China" is an essential resource for companies, investors, and entrepreneurs interested in accessing China's antibody industry. This report offers a comprehensive overview and market analysis, together with a directory of over 30 antibody-related enterprises. GB analysts deliver detailed case studies of industry leaders, along with company profiles. Cost data is included and large-scale manufacturing is also addressed.

December 15, 2004

GB's China Pipeline featured in Nature Magazine article
In December's issue of Nature Magazine, Sabine Lou?t uses GB's unique China Pipeline Report as a jumping off point in a close look at China's burgeoning biotech industry. The article, "Can China bring its own pipeline to the market?", focuses on the opportunities and dangers available to industry players and investors, in a time of rapid innovation and strengthening government regulation.

December 13, 2004

GB publishes Bio-Services in China
GB published Bio-Services in China today, the essential starting point for any research enterprise, investor, or entrepreneur looking to increase R&D productivity and reduce costs through outsourcing. The report includes an overview of the industry, cost comparisons, 8 services categories with company listings and critical equipment employed, 3 case studies, 15 profiles, and a directory of 53 Chinese biotech service companies. As evidenced by Invitrogen's acquisition of Bioasia, there has never been a better time to contemplate the advantages China can bring to your organization.

November 10, 2004

GB publishes Emerging Bio-equipment Manufacturers in China 2004
GB published Emerging Bio-Equipment Manufacturers in China 2004 today, a directory of over 130 Chinese manufacturers, an overview and analysis of the emerging life science laboratory equipment industry in China, 20 profiles of leading companies, and case studies of two typical industry leaders. The publication is essential for multinational life science equipment manufacturers interested in sourcing, OEM or following China's growing industry.

November 10, 2004

GB publishes Reagent & Consumable Manufacturers, China 2004
GB published Reagent and Consumable Manufacturers today, which includes an overview and analysis of the emerging life science reagent and consumable industry in china, a complete directory of over 55 reagent and 30 consumable manufacturers, and 10 profiles of leading companies in the industry. The publication provides a comprehensive resource for multinational life science reagent and consumable manufacturers interested in sourcing, OEM, or following the industry.

October 22, 2004

GB presents at Environmental Biotechnology meeting
GB presented at China's Environmental Microbiology Symposium 2004 to a crowd of scientists and aspiring entrepreneurs. The talk, addressing the market for remediation and other environmental biotechnologies, was followed by talks on entrepreneurship by leadership from Siji Biotechnology.

October 20, 2004

GB publishes Pipeline China 2004, the first collection of innovative drug candidates developed in China
GB published Pipeline China 2004 today, highlighting over 130 new drugs under development in China. The report is a result of extensive research by GB staff members and addresses biologics and small molecules in preclinical and clinical development in China. The publication is essential for business development professionals at pharmaceutical and biotechnology companies interested in potential partnership with Chinese innovators.

September 15, 2004

GB publishes China Biotech 2004, an essential starting point for anyone interested in China\'s emerging biotechnology industry
GB published China Biotech 2004, a directory of the over 250 biotechnology companies and a 30 page overview of biotechnology development in China. The publication focuses on what has been accomplished and what remains to be done in China's fast-growing biotechnology industry.

July 30, 2004

General Biologic updates website, publications available for online purchase
General Biologic completed an update of its website today, adding functionality and information relevant to its client base. New sections include content that explains our services for investors, biotechnology and pharmaceutical companies, and suppliers to the biotechnology industry. Concurrently with the website, GB has initiated an email-based newsletter that will address the Chinese biotechnology industry growth and development.

June 6, 2004

General Biologic becomes one of the few Chinese members of the Biotechnology Industry Association (BIO)
General Biologic has become one of the only companies with primary operations in China to join BIO. We look forward to working together with other members of the organization to address common issues that relate to the biotechnology industry as a whole, and China in particular.